Theratome Bio

Theratome Bio is a pre-clinical biotechnology company established in 2011, headquartered in the United States. The company's focus is on developing a platform of cell-free biologics to target unmet medical needs, covering various therapeutic areas including ischemic brain injury, concussion, acute kidney injury, and increasing the shelf life of donor organs and tissues. Theratome Bio's therapeutics offer advantages over cell-based therapies, including off-the-shelf administration, convenient freezer temperature storage and delivery, and immediate bioavailability. Notably, the company received a Series A investment on 17 October 2018, with the Texas Halo Fund serving as the investing entity. In summary, Theratome Bio presents a compelling case in the biotechnology sector with its innovative approach to addressing unmet medical needs through cell-free biologics. The recent Series A funding from the Texas Halo Fund signifies investor confidence in the company's potential. With a strong focus on addressing critical medical needs and differentiating itself from traditional cell-based therapies, Theratome Bio is positioned for potential growth and impact in the biotechnology industry.